Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...